Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms

Carcinogenesis

Volumn 28, Issue 5, 2007, Pages 1104-1110

  Cho, Hyun Ji ^a   Kang, Jeong Han ^a   Kwak, Jong Young ^b   Lee, Tae Sung ^a   Lee, In Seon ^c   Park, Nam Gyu ^d   Nakajima, Hiroo ^e   Magae, Junji ^f   Chang, Young Chae ^a  

^a Catholic University of Daegu   (South Korea)

^b Dong A University   (South Korea)

^c Keimyung University   (South Korea)

^d Pukyong National University   (South Korea)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f INSTITUTE OF RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; ASCOFURANONE; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR; PHORBOL 13 ACETATE 12 MYRISTATE; SESQUITERPENE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RAT; TRANSCRIPTION REGULATION; TRANSCRIPTION REPRESSION; ANIMAL; CELL CULTURE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ONCOGENE RAS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, RAS; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; RAF KINASES; RATS; SESQUITERPENES; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED;

EID: 34447096817     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl217     Document Type: Article

References (44)

1. Sasaki, H. et al. (1973) Isolation and structure of ascofuranone and ascofranol, antibiotics with hypolipidemic activity. J. Antibiot. (Tokyo), 26, 676-680.
2. Sawada, M. et al. (1973) Hypolipidemic property of ascofuranone. J. Antibiot. (Tokyo), 26, 681-686.
3. Magae, J. et al. (1982) Antitumor protective property of an isoprenoid antibiotic, ascofuranone. J. Antibiot. (Tokyo), 35 1547-1552.
4. Magae, J. et al. (1988) Antitumor and antimetastatic activity of an antibiotic, ascofuranone, and activation of phagocytes. J. Antibiot. (Tokyo), 41, 959-965.
5. Magae, J. et al. (1986) In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system. Cancer Res, 46, 1073-1078.
6. Magae, J. et al. (1986) Activation of natural cytotoxic activity and concomitant reduction of triglyceride content of murine spleen, treated with an antitumor antibiotic, ascofuranone. J. Antibiot. (Tokyo), 39, 676-681.
7. Zucker, S. et al. (1993) M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res, 53, 140-146.
8. Lakka, S.S. et al. (2004) Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene, 23, 4681-4689.
9. Shim, Y.H. et al. (2003) p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett. 190, 213-219.
10. Stetler-Stevenson, W.G. et al. (1996) Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin. Cancer Briol., 7, 147-154.
11. Chambers, A.E et al. (1997) Changing views of the role of matrix metalloproteinases in metastasis. J. Natl Cancer Inst., 89, 260-270.
12. Nabeshima, K. et al. (2002) Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol. Int., 52, 255-264.
13. Arai, K. et al. (2003) Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia, 43, 254-264.
14. Chung, T.W. et al. (2004) Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: Complete regression of hepatoma growth and metastasis by dual mechanism. FASEB J, 18, 1123-1125.
15. Gum, R. et al. (1997) Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signalregulated kinase-dependent signaling cascades. Oncogene, 14, 1481-1493.
16. Eberhardt, W. et al. (2000) Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J. Immunol., 165, 5788-5797.
17. Abiru, S. et al. (2002) Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology, 35, 1117-1124.
18. Kim, D. et al. (2001) Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J, 15, 1953-1962.
19. Sato, T. et al. (2002) Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinasea-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res, 62, 1025-1029.
20. Eferl, R. et al. (2003) AP-1: A double-edged sword in tumorigenesis. Nat. Rev. Cancer, 3, 859--868.
21. Pastore, S. et al. (2005) ERK1/2 regulates epidermal chemokine expression and skin inflammation. J. Immunol., 174, 5047-5056.
22. Park, K.K. et al. (2003) Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP. Biochem. Biophys. Res. Commun., 308, 689-697.
23. Chung, T.W. et al. (2004) Novel and therapeutic-effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: Complete regression of hepatoma growth and metastatis by dual mechanism. FASEB J, 18, 1670-1681.
24. Chae, Y.M. et al. (2004) Spf-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochem Biophys. Res. Commun, 319, 550-555.
25. Mon, N.H. et al. (2006) A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metallproteinase-9 production in a cholangiocarcinoma cell line, CCKS1. Cancer Res, 66, 6778-6784,
26. Kazes, I. et al. (2000) Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: Involvement in MMP2 activation and platelet aggregation. Blood, 96, 3064-3069.
27. Tsuchiya, Y. et al. (1993) Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res, 53, 1397-1402.
28. Sato, H. et al. (1993) v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J. Biol. Chem., 268, 23460-23468.
29. Woo, J.H. et al. (2003) Dykellic acid inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting nuclear factor kappa B transcriptional activity. Cancer Res, 63 3430-3434.
30. Angel, P. et al. (1987) Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell, 49, 729-739.
31. Woo, J.H. et al. (2004) Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene, 23, 1845-1853.
32. Zucker, S. et al. (2000) Critical appraisal of the use of matrix metallo-proteinase inhibitors in cancer treatment. Oncogene, 19 6642-6650.
33. Angel, P. et al. (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta., 1072, 129-157.
34. Vogt, P.K. (2001) Jun, the oncoprotein. Oncogene, 20, 2365-2377.
35. Shaulian, E. et al. (2001) AP-1 in cell proliferation and survival. Oncogene, 20, 2390-2400.
36. Karin, M. (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270, 16483-16486.
37. Casalino, L. et al. (2003) Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent post-translational stabilization. Mol. Cell. Biol., 23, 4401-4415.
38. Vial, E. et al. (2003) Elevated ERK-MAP kinase activity protects the FOS family member FRA- 1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci., 116, 4957-4963.
39. Burch, P.M. et al. (2004) An extracellular signal-regulated kinnase 1- and 2-dependent program of chromatin trafficking of c-Fos and Fra-1 is required for cyclin D1 expression during cell cycle reentry. Mol. Cell. Biol., 24, 4696-4709.
40. Caird, J.J. et al. (2006) Matrix metalloproteinases 2 and 9 in human atherosclerotic and non-atherosclerotic aneurysms. Eur. J. Neurol., 13, 1098-1105.
41. Deguchi, J.O. et al. (2006) Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation, 114, 55-62.
42. Hengor, A. et al. (2004) Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int., 65, 914-917.
43. Philipp, K. et al. (2004) Target TGF-beta in human keratinocytes and its potential role in wound healing, Int. J. Mol. Med., 14 589-593.
44. Ram, M. et al. (2006) Matrix metalloproteinase-9 and autoimmune disease J. Clin. Immunol., 26, 299-307.